Drugs / Q-Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02478450 | Dec 2026 → Dec 2028 expected | amyotrophic lateral sclerosis | Q Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03887273 | Sep 2022 → Jul 2024 | transverse myelitis | Q Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Q-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02478450 ↗ |
| Action | Restore | “Q-Cells® have the potential to repair damage that has occurred” NCT03887273 ↗ |
| Modality | Cell therapy | “cellular therapeutic comprised of human cells of the glial lineage” NCT02478450 ↗ |
| Route | Other | “transplantation (by injection)” NCT02478450 ↗ |